Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @PBOAssoc
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @PBOAssoc
-
PBOA proslijedio/la je Tweet
PRESS RELEASE: Another Record Year for FDA Drug Approvals; 35 approvals in 2019, BioPlan Data https://conta.cc/2RY4yt1 pic.twitter.com/rH9gR1ChQL
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PBOA proslijedio/la je Tweet
.
@PharmaPinkSheet unveiled a four-story preview of the upcoming user fee reauthorization process today. Here's a graphic looking at schedule:https://pink.pharmaintelligence.informa.com/PS141551/Predicting-The-User-Fee-Reauthorization-Schedule …Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New
@VelescoPharma clinical manufacturing facility begins operations (PDF) http://www.velescopharma.com/Userfiles/PDFs/VelescoPressReleaseNewFacility-04-Feb-2020.pdf …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and Biosimilars Products into New Company (PDF) https://merck.unleashinggrowthpotential.com/wp-content/uploads/2020/02/news_release_02_05_2020.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
LSNE Expands Vial Filling And Lyophilization Capacity With Isolator Technologyhttps://www.prnewswire.com/news-releases/lsne-expands-vial-filling-and-lyophilization-capacity-with-isolator-technology-300999003.html …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Merck to Spin Off Slow-Growth Products Into New Company - WSJhttps://www.wsj.com/articles/merck-to-spin-off-slow-growth-products-into-new-company-11580903102 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Trefoil Therapeutics Selects
@AGCBiologics as Lead Manufacturer of TTHX1114 for Treatment of Corneal Diseaseshttps://www.prnewswire.com/news-releases/trefoil-therapeutics-selects-agc-biologics-as-lead-manufacturer-of-tthx1114-for-treatment-of-corneal-diseases-300994867.html …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Navrogen and Levena Announce Collaboration to Develop Antibody Drug Conjugates (ADCs) to Treat Humoral Immuno-Suppressed Cancershttps://www.prnewswire.com/news-releases/navrogen-and-levena-announce-collaboration-to-develop-antibody-drug-conjugates-adcs-to-treat-humoral-immuno-suppressed-cancers-300998647.html …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Piramal Enterprises Limited Q3 & 9M FY2020 Results (PDF) https://piramal.com/assets/pdf/financial_quaterly_returns/PEL_Q3_9M_FY20_Results_Presentation_vFinal3.pdf …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PBOA proslijedio/la je Tweet
Hosted in partnership with
@OneNucleus, this workshop will show how a comprehensive end-to-end#biologics solution has the potential to provide higher quality and improved yield of#biopharmaceuticals with reduced cost and time. Attend this free event:http://ow.ly/xh5o50y6MY9Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Member event:
@masybioservices Insacal Conductivity Meter Demo Day, Feb. 26, 2020https://masy.com/index.php/event/insacal-conductivity-meter-demo-day/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Samsung Biologics Reports 64% Jump in FY19 Earnings, Sees Global Expansion in 2020https://www.prnewswire.com/news-releases/samsung-biologics-reports-64-jump-in-fy19-earnings-sees-global-expansion-in-2020-300998185.html …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalent, Inc. Reports Second Quarter Fiscal 2020 Results | Business Wirehttps://www.businesswire.com/news/home/20200203005170/en/Catalent-Reports-Quarter-Fiscal-2020-Results …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PBOA proslijedio/la je Tweet
Breaking: Catalent
$CTLT to buy Orgenesis'#celltherapy#CDMO biz Masthercell for $315m - story@BioProInsider Insider https://buff.ly/36PRRod pic.twitter.com/gdXg2Jb6nZ
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Pfizer's CDMO unit drives growth at hospital businesshttps://www.outsourcing-pharma.com/Article/2020/02/03/Pfizer-s-CDMO-unit-drives-growth-at-hospital-business …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Globalhttps://biologics.catalent.com/catalent-news/catalent-to-acquire-leading-cell-therapy-company-masthercell-global/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
PBOA proslijedio/la je Tweet
Catalent To Acquire Leading Cell Therapy Company MaSTherCell Global for $315 Million, Creating an Industry-Leading Cell & Gene Therapy Platform Read more: http://ow.ly/jawX50ybOMV
#pressrelease#celltherapypic.twitter.com/BfpOGHkxz3
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
ILC Dover Announces Growth Partnership with New Mountain Capitalhttps://www.businesswire.com/news/home/20200203005262/en/ILC-Dover-Announces-Growth-Partnership-New-Mountain …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
This week's
@PBOAssoc went out this a.m., feat. news from@thermofisher@vetterpharma@CatalentPharma@PiramalPharma@pfizer@TraceLink@MCMasterControl & more! Read/subscribe:https://mailchi.mp/pharma-bio/vetter-piramal-thermo …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.